Concepts (60)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 5 | 2022 | 132 | 1.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 266 | 0.780 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2020 | 8 | 0.720 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 18 | 0.720 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2018 | 199 | 0.680 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2017 | 7 | 0.610 |
Why?
|
| Neoplasms | 5 | 2021 | 1667 | 0.610 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2017 | 195 | 0.520 |
Why?
|
| Cytokines | 2 | 2020 | 866 | 0.510 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 529 | 0.440 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 91 | 0.350 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 213 | 0.320 |
Why?
|
| Th17 Cells | 2 | 2020 | 116 | 0.310 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2019 | 135 | 0.300 |
Why?
|
| Melanoma | 2 | 2022 | 335 | 0.300 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 597 | 0.270 |
Why?
|
| Animals | 7 | 2022 | 20881 | 0.200 |
Why?
|
| Carrier State | 1 | 2021 | 39 | 0.190 |
Why?
|
| Mice | 4 | 2022 | 8474 | 0.190 |
Why?
|
| Immunotherapy | 2 | 2021 | 215 | 0.180 |
Why?
|
| Adoptive Transfer | 2 | 2018 | 100 | 0.180 |
Why?
|
| Acid Ceramidase | 1 | 2021 | 85 | 0.180 |
Why?
|
| Isoquinolines | 1 | 2020 | 37 | 0.180 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 186 | 0.180 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 34 | 0.180 |
Why?
|
| B-Lymphocytes | 1 | 2022 | 329 | 0.170 |
Why?
|
| Sphingosine | 1 | 2021 | 315 | 0.170 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 397 | 0.170 |
Why?
|
| Energy Metabolism | 1 | 2021 | 222 | 0.170 |
Why?
|
| Pyrazoles | 1 | 2020 | 190 | 0.160 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.160 |
Why?
|
| Sphingolipids | 1 | 2021 | 337 | 0.150 |
Why?
|
| Transplantation Chimera | 1 | 2017 | 10 | 0.150 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 126 | 0.150 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 138 | 0.150 |
Why?
|
| Mice, SCID | 1 | 2017 | 238 | 0.150 |
Why?
|
| Autoimmunity | 1 | 2018 | 118 | 0.140 |
Why?
|
| Interleukin-10 | 1 | 2017 | 144 | 0.140 |
Why?
|
| Pancreas | 1 | 2017 | 225 | 0.140 |
Why?
|
| Sex Factors | 1 | 2017 | 1266 | 0.120 |
Why?
|
| Humans | 9 | 2022 | 68618 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2550 | 0.090 |
Why?
|
| Male | 3 | 2022 | 37321 | 0.050 |
Why?
|
| Female | 3 | 2022 | 38074 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2021 | 228 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 35 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2020 | 330 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 446 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2018 | 35 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 186 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1593 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 2791 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 729 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 4848 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 8912 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7029 | 0.020 |
Why?
|
| Aged | 1 | 2021 | 14862 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 21147 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 21403 | 0.010 |
Why?
|